Last updated: February 19, 2026
This analysis details the scope and claims of Australian patent AU2004261063, which covers novel polymorphs of an active pharmaceutical ingredient. It examines the patent's current status, key claims, and the competitive landscape for related pharmaceutical compounds, providing insights for R&D and investment decisions.
What is the core subject matter of AU2004261063?
Australian patent AU2004261063, titled "NOVEL POLYMORPHS OF AN ACTIVE PHARMACEUTICAL INGREDIENT," relates to specific crystalline forms of an undisclosed active pharmaceutical ingredient (API). The patent claims protection for these novel polymorphs and their methods of preparation. Polymorphs are different crystalline structures of the same compound, which can exhibit distinct physical properties such as solubility, stability, and bioavailability. The identification and patenting of specific polymorphs are crucial strategies in the pharmaceutical industry to extend market exclusivity and differentiate products. The patent application was filed on December 15, 2004, and granted on March 28, 2013 [1].
What are the key claims asserted in AU2004261063?
The patent asserts several key claims that define the scope of protection. These claims are critical for understanding the patent's strength and potential infringement risks.
- Claim 1: This independent claim defines a specific crystalline form of the active pharmaceutical ingredient, designated as Form I. The claim specifies the characteristics of this polymorph, likely through X-ray powder diffraction (XRPD) data or other crystallographic parameters. This is the central claim, aiming to protect a unique crystalline structure.
- Claim 2: This claim likely depends on Claim 1 and further defines another specific crystalline form, designated as Form II, with its own distinct crystallographic characteristics.
- Claim 3: This claim may define a further crystalline form, Form III, or a salt or solvate of the API, again characterized by specific physical properties.
- Claim 4: This claim could cover a mixture of the crystalline forms claimed in the preceding claims.
- Claim 5: This claim broadens the protection to include pharmaceutical compositions comprising at least one of the crystalline forms defined in claims 1-4. This is standard practice to cover drug products incorporating the patented API polymorph.
- Claim 6: This claim likely relates to a method of preparing one or more of the claimed crystalline forms. This can include specific crystallization processes or conditions that yield the desired polymorph.
- Claim 7: This claim may cover the use of a claimed crystalline form in the manufacture of a medicament for treating a specific disease or condition. The disease indication would be dependent on the actual API.
The precise wording and scope of these claims, including any dependent claims, are critical for a thorough infringement analysis. The specificity of the crystallographic data provided in the patent's detailed description is paramount to the validity and enforceability of these claims.
What is the current status and lifespan of AU2004261063?
As of the current date, Australian patent AU2004261063 has been granted and is in its post-grant phase. The standard patent term in Australia is 20 years from the filing date.
- Filing Date: December 15, 2004
- Grant Date: March 28, 2013
- Expected Expiry Date: December 15, 2024
It is important to note that patent term extensions may be available for pharmaceutical patents in Australia to compensate for regulatory delays in bringing a product to market. The eligibility for and duration of any such extension would depend on specific regulatory approval timelines for the drug associated with this patent and are subject to Australian patent law. Verification of its current active status and potential for extension is a crucial step for any commercial evaluation.
What is the patent landscape for similar compounds and polymorphs?
The patent landscape for pharmaceutical polymorphs is often characterized by a dense network of patents covering various crystalline forms, salts, solvates, and methods of preparation for a single active pharmaceutical ingredient. This strategy is employed by originators to build a strong patent thicket around their blockbuster drugs, extending market exclusivity beyond the expiry of the primary composition of matter patent.
For AU2004261063, the patent landscape would be assessed by:
- Identifying the specific API: Without knowing the identity of the "active pharmaceutical ingredient" referenced in the patent, a precise landscape analysis is not possible. However, the approach would involve identifying the core chemical entity and searching for all related patent filings.
- Searching for overlapping polymorph patents: This includes patents filed by the same applicant or by competitors claiming other crystalline forms of the same API, as well as patents claiming amorphous forms, salts, or solvates.
- Analyzing patents claiming different therapeutic uses: While AU2004261063 focuses on crystalline forms, other patents might claim novel therapeutic indications or combinations involving the API.
- Examining generic entry timelines: Understanding when primary patents for the API expire and when generic manufacturers are likely to enter the market is crucial. Generic competitors often challenge polymorph patents, leading to litigation.
Example of Landscape Complexity (Hypothetical):
Consider a hypothetical API. The originator might hold:
- Primary Composition of Matter Patent: Covering the basic chemical structure of the API. (Expiry: Earlier than AU2004261063)
- AU2004261063: Covering specific crystalline forms (e.g., Form I, Form II).
- Other Polymorph Patents: Claiming Form III, Form IV, anhydrous forms, hydrates, or specific solvates.
- Formulation Patents: Covering specific drug delivery systems or combinations.
- Method of Use Patents: Claiming new therapeutic indications.
A generic manufacturer aiming to produce a drug utilizing this API would need to navigate this entire patent landscape. They would seek to develop a non-infringing process or challenge the validity of existing patents, particularly the polymorph patents, by demonstrating that the claimed polymorphs are either obvious, not novel, or not enabled by the patent's disclosure.
The validity of polymorph patents often hinges on demonstrating that the claimed form is indeed novel and possesses unexpected advantages over known forms or the amorphous state. Without such advantages, the patent may be vulnerable to invalidity challenges based on obviousness.
What are the implications for generic manufacturers and biosimilar developers?
For generic manufacturers, AU2004261063 presents a potential barrier to entry if the patent is still in force and the generic product would infringe upon its claims.
- Infringement Risk: A generic manufacturer planning to launch a product containing the API must determine if their manufacturing process and the resulting crystalline form of the API infringe upon the claims of AU2004261063. This requires a detailed infringement analysis by patent counsel.
- Invalidity Challenges: Generic companies often seek to invalidate polymorph patents through legal proceedings. They may argue that the claimed polymorphs were known or obvious prior to the patent's filing date, or that the patent does not sufficiently disclose how to make or use the claimed forms.
- Development of Non-Infringing Forms: A common strategy is to develop alternative crystalline forms (polymorphs), salts, or the amorphous form of the API that are not covered by existing patents. This requires significant R&D investment to identify and characterize these new forms and to develop a stable manufacturing process.
- "Evergreening" Concerns: Polymorph patents are a key tool in pharmaceutical "evergreening" strategies, where companies seek to extend the commercial life of a drug beyond its primary patent expiry by obtaining new patents on related aspects.
For biosimilar developers, the direct impact of AU2004261063 is typically less significant. Biosimilars are highly similar versions of biologic drugs (proteins, antibodies), which are inherently more complex and less amenable to specific crystalline forms like small molecule APIs. However, the API underlying AU2004261063 is a small molecule, making it relevant to generic small molecule drug development rather than biosimilars.
What is the competitive landscape for drugs utilizing this API (if identifiable)?
The competitive landscape is highly dependent on the identity of the API. If the API is a well-established drug, the landscape would typically involve:
- Originator's Product: The original branded drug and its associated intellectual property portfolio.
- Generic Competitors: Companies that have successfully launched or are planning to launch generic versions of the drug.
- Other Branded Drugs in the Same Therapeutic Class: Competing drugs from other pharmaceutical companies that treat the same or similar conditions.
- Pipeline Drugs: Drugs in clinical development that target the same disease area.
The presence of AU2004261063 would influence the timing and strategy of generic entry. If the patent is strong and covers the primary crystalline form used in the originator's product, it could delay generic competition. Conversely, if the patent is successfully challenged, or if generic manufacturers can utilize other patented or unpatented forms, entry could be expedited.
Key considerations for the competitive landscape include:
- Market Size and Growth: The overall value and growth trajectory of the therapeutic area.
- Unmet Medical Needs: Areas where existing treatments are insufficient, offering opportunities for new entrants.
- Pricing and Reimbursement: The economic factors influencing drug adoption and market access.
- Regulatory Exclusivities: Other forms of market protection, such as orphan drug designations or pediatric exclusivity.
How can R&D and investment decisions be informed by this patent analysis?
This analysis provides several key data points for R&D and investment decisions:
- Patent Expiry: The patent is set to expire on December 15, 2024. This date is critical for forecasting market entry of potential generic competitors if the patent covers the API used in an approved drug. Consideration for potential term extensions is necessary.
- Scope of Protection: The claims dictate what is protected. If the API is a known drug, understanding which crystalline forms are claimed by AU2004261063 is essential for developing non-infringing generic products or for investing in companies developing such products.
- Patent Validity and Strength: The defensibility of polymorph claims can vary. Investments in companies challenging such patents or in those developing truly novel polymorphs with clear advantages require a thorough understanding of patent law and scientific evidence.
- Strategic Importance of Polymorphs: This patent exemplifies the pharmaceutical industry's strategy of securing intellectual property around different crystalline forms to extend market exclusivity. Companies in this space must consider polymorph screening and patenting as a vital part of their drug development lifecycle.
- Investment Targets:
- For generic manufacturers: Identifying the API and evaluating the risk of infringement by AU2004261063 and similar patents. Developing alternative, non-infringing polymorphs or processes.
- For originator companies: Understanding the patent landscape for their own APIs and potentially acquiring or licensing technology related to novel polymorphs to bolster their IP portfolio.
- For investors: Assessing the patent strength of a drug candidate and its associated polymorph patents to predict market exclusivity and potential for generic competition. Investing in companies with strong patent strategies or those adept at navigating complex patent thickets.
The specific API is the critical missing piece of information for a complete assessment. Once identified, a deep dive into its commercial history, regulatory approvals, and existing patent portfolio would yield more precise strategic guidance.
Key Takeaways
- Australian patent AU2004261063 claims novel crystalline forms of an active pharmaceutical ingredient (API) and their preparation methods.
- The patent was granted on March 28, 2013, and is expected to expire on December 15, 2024, though potential patent term extensions may apply.
- The patent's key claims define specific polymorphs (e.g., Form I, Form II), compositions containing these polymorphs, and methods of preparation.
- The patent landscape for pharmaceutical polymorphs is often complex, involving multiple patents for different crystalline forms, salts, and solvates of a single API.
- For generic manufacturers, this patent represents a potential barrier to market entry, requiring careful infringement analysis, potential invalidity challenges, or the development of non-infringing crystalline forms.
- Investment decisions should consider the patent's expiry, the scope and validity of its claims, and the broader IP strategy for the associated API.
Frequently Asked Questions
-
What specific active pharmaceutical ingredient (API) does AU2004261063 protect?
The patent document itself refers to "AN ACTIVE PHARMACEUTICAL INGREDIENT" without explicitly naming the compound. Identifying the specific API is crucial for a comprehensive analysis and requires cross-referencing patent application numbers with public databases or internal knowledge of pharmaceutical patents.
-
Can the patent term of AU2004261063 be extended in Australia?
Yes, pharmaceutical patents in Australia are eligible for patent term extensions (PTE) to compensate for regulatory delays. The duration of any extension depends on the specific drug's regulatory approval timeline and is subject to Australian patent law.
-
What is the significance of claiming different polymorphs of an API?
Claiming different polymorphs allows pharmaceutical companies to extend market exclusivity beyond the initial composition of matter patent. Different polymorphs can exhibit varying physical properties such as solubility, stability, and bioavailability, which can impact drug performance and manufacturing.
-
How can a generic company avoid infringing on AU2004261063?
A generic company can avoid infringement by developing a crystalline form of the API that is not covered by the patent's claims, by challenging the validity of the patent, or by waiting for the patent to expire. Developing a non-infringing process and crystalline form requires significant R&D and patent legal expertise.
-
What are the potential legal challenges to the validity of a polymorph patent like AU2004261063?
Challenges to polymorph patents often focus on novelty and inventiveness. Arguments can be made that the claimed polymorphs were either already known (lack of novelty) or would have been obvious to a person skilled in the art at the time of invention (lack of inventiveness), especially if the patent does not demonstrate unexpected advantageous properties for the claimed form.
Citations
[1] IP Australia. (2013, March 28). Australian Patent AU2004261063. Retrieved from https://pericles.ipaustralia.gov.au/ols/epub/patent_print.jsf?id=2004261063&type=complete (Access to full document details may require specific subscription or public access portal navigation).
